

| Project Title | Funding | Strategic Plan Objective | Institution |
|---|-----------|--------------------------|--|
| Redox abnormalities as a vulnerability phenotype for autism and related alterations in CNS development | \$0 | Q2.S.A | Arkansas Children's Hospital Research Institute |
| Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2 | \$0 | Q3.Other | Burnham Institute |
| Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1 | \$0 | Q3.Other | Burnham Institute |
| Multiplexed suspension arrays to investigate newborn and childhood blood samples for potential immune biomarkers of autism | \$0 | Q1.L.A | Centers for Disease Control and Prevention (CDC) |
| The functional link between DISC1 and neuroligins: Two genetic factors in the etiology of autism | \$110,250 | Q2.S.D | Children's Memorial Hospital, Chicago |
| Immunopathogenesis in autism: Regulatory T cells and autoimmunity in neurodevelopment | \$106,609 | Q3.S.F | East Carolina University |
| Mechanisms of mitochondrial dysfunction in autism | \$489,354 | Q2.S.A | Georgia State University |
| Maternal risk factors for autism spectrum disorders in children of the Nurses' Health Study II | \$0 | Q3.L.C | Harvard University |
| Maternal risk factors for autism spectrum disorders in children of the Nurses' Health Study II | \$0 | Q3.L.C | Harvard University |
| Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD) | \$801,970 | Q4.S.C | Holland Bloorview Kids Rehabilitation Hospital |
| Receptive vocabulary knowledge in low-functioning autism as assessed by eye movements, pupillary dilation, and event-related potentials | \$615,000 | Q1.Other | Johns Hopkins University |
| Discordant monozygotic twins as a model for genetic-environmental interaction in autism | \$0 | Q3.S.C | Johns Hopkins University |
| MeHG stimulates antiapoptotic signaling in stem cells | \$0 | Q3.Other | Kennedy Krieger Institute |
| Discordant monozygotic twins as a model for genetic-environmental interaction in autism | \$0 | Q3.S.C | Kennedy Krieger Institute |
| Identification of lipid biomarkers for autism | \$249,924 | Q1.L.A | Massachusetts General Hospital |
| A prospective multi-system evaluation of infants at risk for autism | \$0 | Q1.L.B | Massachusetts General Hospital |
| A prospective multi-system evaluation of infants at risk for autism | \$0 | Q1.L.B | Massachusetts General Hospital |
| Analysis of the small intestinal microbiome of children with autism | \$132,750 | Q2.Other | Massachusetts General Hospital |
| Maternal risk factors for autism spectrum disorders in children of the Nurses' Health Study II | \$0 | Q3.L.C | Massachusetts General Hospital |
| Development of a high-content neuronal assay to screen therapeutics for the treatment of cognitive dysfunction in autism spectrum disorders | \$597,637 | Q4.S.B | Massachusetts Institute of Technology |
| The transcription factor PLZF: A possible genetic link between immune dysfunction and autism | \$142,113 | Q3.Other | Memorial Sloan-Kettering Cancer Center |
| Development of an internet-based parent training intervention for children with ASD | \$552,530 | Q5.L.A | Michigan State University |
| Placental vascular tree as biomarker of autism/ASD risk | \$483,029 | Q1.L.A | Research Foundation for Mental Hygiene, Inc. |

| Project Title | Funding | Strategic Plan Objective | Institution |
|---|-----------|--------------------------|---|
| Characterization of the pathological and biochemical markers that correlate to the clinical features of autism | \$0 | Q2.Other | Research Foundation for Mental Hygiene, Inc. |
| Characterization of the pathological and biochemical markers that correlate to the clinical features of autism | \$0 | Q2.Other | Research Foundation for Mental Hygiene, Inc. |
| Characterization of the pathological and biochemical markers that correlate to the clinical features of autism | \$0 | Q2.Other | Research Foundation for Mental Hygiene, Inc. |
| Redox abnormalities as a vulnerability phenotype for autism and related alterations in CNS development | \$0 | Q2.S.A | State University of New York at Potsdam |
| Toxicant-induced autism and mitochondrial modulation of nuclear gene expression | \$0 | Q3.S.F | Texas A&M University |
| Gastrointestinal functions in autism | \$0 | Q2.S.E | University at Buffalo, The State University of New York |
| Role of autism-susceptibility gene, CNTNAP2, in neural circuitry for vocal communication | \$573,420 | Q2.Other | University of California, Los Angeles |
| Improving synchronization and functional connectivity in autism spectrum disorders through plasticity-induced rehabilitation training | \$487,384 | Q4.Other | University of California, San Diego |
| Abnormal vestibulo-ocular reflexes in autism: A potential endophenotype | \$510,142 | Q1.L.A | University of Florida |
| Self-injurious behavior: An animal model of an autism endophenotype | \$107,918 | Q2.S.G | University of Florida |
| Etiology of sleep disorders in ASD: Role of inflammatory cytokines | \$0 | Q2.S.E | University of Maryland, Baltimore |
| Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial | \$0 | Q4.L.A | University of Medicine & Dentistry of New Jersey |
| Epigenetic regulation of the autism susceptibility gene, ENGRAILED 2 (EN2) | \$0 | Q3.Other | University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School |
| Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial | \$0 | Q4.L.A | University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School |
| Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial | \$0 | Q4.L.A | University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School |
| Atypical pupillary light reflex in individuals with autism | \$515,419 | Q1.Other | University of Missouri |
| Novel strategies to manipulate Ube3a expression for the treatment of autism and Angelman syndrome | \$111,000 | Q4.Other | University of North Carolina at Chapel Hill |
| Redox abnormalities as a vulnerability phenotype for autism and related alterations in CNS development | \$0 | Q2.S.A | University of Rochester |
| Systematic characterization of the immune response to gluten and casein in autism spectrum disorders | \$126,432 | Q1.Other | Weill Cornell Medical College |
| Biomarkers for autism and for gastrointestinal and sleep problems in autism | \$472,129 | Q1.L.A | Yale University |

